

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
| Cholangiocarcinoma | D018281 | — | C22.1 | — | 1 | — | — | — | 1 |
| Biliary tract neoplasms | D001661 | — | C24.9 | — | 1 | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | — | 1 | — | — | — | 1 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Nasopharyngeal carcinoma | D000077274 | — | — | — | 1 | — | — | — | 1 |
| Nasopharyngeal neoplasms | D009303 | — | — | — | 1 | — | — | — | 1 |
| Drug common name | Bintrafusp alfa |
| INN | bintrafusp alfa |
| Description | Bintrafusp alfa is a protein pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against programmed cell death 1 ligand 1. |
| Classification | Protein |
| Drug class | fusion proteins |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298024 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | NW9K8C1JN3 (ChemIDplus, GSRS) |

